CBD-Intel

Premium reports CBD as a Novel Food: the future for edibles in Europe
0

CBD as a Novel Food: the future for edibles in Europe

Published: 27th August 2020 | No. pages: 34
$1,499.00
Free Sample

Request offline purchase

Description

The question of Novel Food approval is the single biggest issue facing the CBD edibles market, and perhaps the entire CBD market, in Europe. Hopes that there might be an easy way around the regulatory requirement seem unrealistic, and understanding exactly what the Novel Food process entails must therefore now be a top priority for any player hoping to market mainstream CBD products in Europe.

This report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway. Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.

This report also includes a 1-hour consultation call related to Novel Food with CBD-Intel’s analyst team.

New report guarantee

If you purchase a report that is updated in the next 60 days, we will send you the new report for free.

Reasons to buy

 

• Take the first steps toward making a Novel Food application.

• Gain in-depth understanding of Novel Food regulation and its practical effects.

• Make an informed decision on whether to apply for Novel Food status.

• Understand the key factors in success and failure.

• Assess the likely business impacts.

• Ensure your European CBD strategy is coherent and joined-up across jurisdictions.

• Identify the specific benefits and challenges of the UK market.

 

*If you choose to subscribe to CBD-Intel within 30 days of purchasing the report, we will credit the price to your first year’s subscription.

Table of contents

  1. Executive summary
  2. Introduction: what is CBD?
  3. Is CBD in food really “novel”?
  4. CBD in food: the market for ingestible products
  5. Novel Food Regulations in the EU
    1. Summary
    2. Is CBD a food product?
    3. Are there CBD products which may not be considered food products?
    4. Could CBD be excluded from EU regulation as an illegal narcotic?
    5. Background to Novel Food regulations in the EU
    6. New EU Novel Food Regulations applied from 2018
    7. What does “consumed to a significant degree” mean?
    8. What is the view of regulators and other stakeholders?
    9. The Novel Food Catalogue
    10. Generic vs applicant-specific Novel Food approval, and data protection
    11. The RASFF system
    12. The Novel Food approval process
    13. Enforcement in the EU
    14. Relevant EU legislation
  6. The regulation of Novel Foods in the UK
    1. Deadline for UK Novel Food applications
    2. Generic vs applicant-specific applications
    3. After 31st March 2021
  7. Other non-EU countries
    1. Switzerland
    2. Norway
  8. Industry impact of Novel Food applications: the costs
  9. Industry impact of Novel Food applications: the benefits
  10. Conclusion: what does the future hold for the CBD sector in Europe?
  11. About CBD-Intel

Methodology

CBD as a Novel Food: the future for edibles in Europe is entirely based on original research by the full-time, sector-dedicated regulatory and market analysis teams at CBD-Intel, available only to purchasers of this report. Research methods contributing to the report include quantitative analysis of market data and trends, forecasting, legislation analysis, conversations with regulators and other stakeholders, and analysis of existing Novel Foods approvals as a potential model for CBD edibles.

Latest reports

Description

The question of Novel Food approval is the single biggest issue facing the CBD edibles market, and perhaps the entire CBD market, in Europe. Hopes that there might be an easy way around the regulatory requirement seem unrealistic, and understanding exactly what the Novel Food process entails must therefore now be a top priority for any player hoping to market mainstream CBD products in Europe.

This report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway. Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.

This report also includes a 1-hour consultation call related to Novel Food with CBD-Intel’s analyst team.

Last Products

Get a free sample of this premium report:

“ CBD as a Novel Food: the future for edibles in Europe ”





    -

    “ CBD as a Novel Food: the future for edibles in Europe ”





      Featured topic

      The Food and Drug Administration (FDA) rejected applications to use hemp extract as a dietary supplement.

      Here are the conclusions we have attracted. CBD-Intel will continue to work on providing answers to the various questions that have arisen.

      Blog | Policy and politics | US federal regulation

      Sign up to our newsletter

      By signing up you agree to our Terms and Conditions